Download PDF
Hamostaseologie 1985; 05(02): 75-81
DOI: 10.1055/s-0038-1655103
Originalarbeiten
Schattauer GmbH

Hämostase bei gestörter Leberfunktion

G. Oehler
1   Zentrum für Innere Medizin der Universität Gießen (Direktor: Prof. Dr. Dr. h. c. H. G. Lasch)
,
H. Heckers
1   Zentrum für Innere Medizin der Universität Gießen (Direktor: Prof. Dr. Dr. h. c. H. G. Lasch)
› Author Affiliations
Further Information

Publication History

Publication Date:
22 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • LITERATUR

  • 1 Abildgaard FCh. Hazards of prothrombin-complex concentrates in treatment of hemophilia. New Engl. J. Med. 304: 670 1981;
    PubMedGoogle Scholar
  • 2 Aoki N, Yamanaka T. The a2-plasmin inhibitor levels in liver diseases. Clin. Chim. Acta. 84: 99 1978;
    CrossrefPubMedGoogle Scholar
  • 3 Aurousseau M. H, Angeli J. L, Josso F. Antithrombin III versus prothrombin in liver cirrhosis. Haemostasis. 10: 104 1981;
    PubMedGoogle Scholar
  • 4 Baele G, Matthies E, Barbier F. Antihaemophilic factor A activity, F VIII-related antigen and von Willebrand factor in hepatic cirrhosis. Acta haematol. 57: 290 1977;
    CrossrefPubMedGoogle Scholar
  • 5 Barckow D, Schwigon C. D, Sultie J. W. Die Wirksamkeit von Vitamin K zur Therapie und Prophylaxe Moxalactaminduzierter Hypoprothrombinämien. Umweltmedizin. 04: 68 1984;
    PubMedGoogle Scholar
  • 6 Bechthold H, Andrassy K, Jähnchen E, Koderisch J, Koderisch H, Weilemann L. S, Sonntag H. G, Ritz E. Evidence for impaired hepatic vitamin K! metabolism in patients treated with N-Methyl-Thiotetrazole Cephalosporins. Thromb. Haemostas. 51: 358 1984;
    PubMedGoogle Scholar
  • 7 Bechthold H, Weilemann L. S, Lorenz J, Andrassy K, Frank D, Meinertz T, Jähnchen E. Cumarinähnliche Wirkung von Cephalosporinen. Verh. Dt. Ges. Inn. Med. 90: 953 1984;
    PubMedGoogle Scholar
  • 8 Bick R. L, Bick M. D, Fekete L. F. Antithrombin III patterns in disseminated intravascular coagulation. Amer. J. Clin. Path. 04: 577 1980;
    PubMedGoogle Scholar
  • 9 Biland L, Duckert F, Prisender S, Nymann D. Quantitative estimation of coagulation factors in liver disease. The diagnostic und prognostic value of factor XIII, factor V and plasminogen. Thromb. Haemostas. 39: 646 1978;
    PubMedGoogle Scholar
  • 10 Birgens H. S, Henriksen J, Mathen P, Poulsen H. The shock liver. Acta Med. Scand. 204: 417 1978;
    PubMedGoogle Scholar
  • 11 Blanchard R. A, Furie B. C, Jörgensen M, Gruger S. F, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. New Engl. J. Med. 305: 242 1981;
    CrossrefPubMedGoogle Scholar
  • 12 Blatt P. M, Lundblad R. L, Kingdon H, Roberts H. K. Thrombogenic materials in prothrombin complex concentrates. Ann. intern. Med. 81: 766 1972;
    PubMedGoogle Scholar
  • 13 Bloom A. L. Intravascular coagulation and the liver. Brit. J. Haemat. 30: 1 1975;
    CrossrefPubMedGoogle Scholar
  • 14 Brunswig D, Liehr H, Richter E. Verbrauchskoagulopathie bei toxischer Leberschädigung durch Knollenblätterpilzvergiftung. Dtsch. med. Wschr. 97: 1347 1972;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Brunswig D. Hepatologische Aspekte des FVIII-assoziierten Antigens. Habilschrift Würzburg. 1976
    PubMedGoogle Scholar
  • 16 Clark R, Borirakchangavat V, Gazzard B. G, Rake M. O, Shilkin K. B, Flute P. T, Williams R. Disordered hemostasis in liver damage from paracetamol overdose. Gastroenterology. 65: 788 1973;
    PubMedGoogle Scholar
  • 17 Coccheri S, Palereti G, Dalmonte P. R, Poggi M, Boggian O. Investigations on intravascular coagulation in liver disease: soluble fibrin monomer complexes in liver cirrhosis. Haemostasis. 08: 8 1979;
    PubMedGoogle Scholar
  • 18 Colombi A. Early diagnosis of fatal hepatitis. Digestion. 03: 129 1970;
    CrossrefPubMedGoogle Scholar
  • 19 Cordova C, Musca A, Violi F, Alessandri C, Vezza E. Improvement of some blood coagulation factors in cirrhotic patients treated with low doses of heparin. Scand. J. Haematol. 29: 235 1982;
    PubMedGoogle Scholar
  • 20 Cordova C, Musca A, Violi F, Alessandri C, Ferro D, Piromalli A, Balsano F. Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients. Haemostasis. 14: 218 1984;
    PubMedGoogle Scholar
  • 21 Corrigan J. J, Jeter M, Earnest D. L. Prothrombin antigen and coagulant activity in patients with liver disease. JAMA. 248: 1736 1982;
    CrossrefPubMedGoogle Scholar
  • 22 Doody P. T. Disopyramide hepatotoxicity and disseminated intravascular coagulation. South Med. J. 75: 496 1982;
    CrossrefPubMedGoogle Scholar
  • 23 Dymock J. W, Tucken J. S, Woolf J. L, Poller L, Thomson J. M. Coagulation studies as a prognostic index in acute liver failure. Brit. J. Haemat. 29: 385 1975;
    CrossrefPubMedGoogle Scholar
  • 24 Francis J. L, Armstrong D. J. Fibrinogen-bound sialic acid levels in the dysfibrinogenaemia of liver disease. Haemostasis. 11: 215 1982;
    PubMedGoogle Scholar
  • 25 Francis J. L, Armstrong D. J. Acquired dysfibrinogenaemia in liver disease. J. Clin. Path. 35: 667 1982;
    CrossrefPubMedGoogle Scholar
  • 26 Francis J. L, Sommonds V. L, Armstrong D. J. Fibrinogen-bound sialic acid and liver sialyltransferase activity in an experimental animal model of cirrhosis. Throb. Haemostas. 50: 202 1983;
    PubMedGoogle Scholar
  • 27 Frick W. Thrombocytopenie und Leberzirrhose. Schweiz. Med. Wschr. 97: 407 1967;
    PubMedGoogle Scholar
  • 28 Fritsche H. M, Sternberger A, Sommoggy S. v, Fischer M, Blümel G. Zur Pathogenese des Gerinnungsdefektes im akuten Leberversagen. Med. Welt. 32: 390 1981;
    PubMedGoogle Scholar
  • 29 Fujii M, Yasunaga K, Uchino H. Correlation analysis of relationships between vitamin K-dependent clotting factor and effective hepatic blood flow, albumin and other liver function tests. Haemostasis. 09: 9 1980;
    PubMedGoogle Scholar
  • 30 Gazzard B. G, Lewis M. L, Ash G, Rizza C. R, Bidwell E, Williams R. Coagulation factor concentrates in the treatment of haemorrhagic diathesis of fulminant hepatic failure. Gut. 15: 993 1974;
    CrossrefPubMedGoogle Scholar
  • 31 Gazzard B. G, Clarke R, Borirakchangavat Y, Williams R. A controlled trial of heparin therapy in the coagulation defect of paracetamol induced hepatic necrosis. Gut. 15: 89 1974;
    CrossrefPubMedGoogle Scholar
  • 32 Gazzard B. G, Portmann B, Murray-Lyon I. M, Williams R. Courses of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. Q. J. Med. 44: 615 1975;
    PubMedGoogle Scholar
  • 33 Gazzard B. G, Henderson J. M, Willams R. Factor VII-levels as a guide to prognosis in fulminant hepatic failure. Gut. 17: 489 1976;
    CrossrefPubMedGoogle Scholar
  • 34 Girolami A, Padrasti G, Cappellato G, Quaino V. An immunological study of prothrombin in liver cirrhosis. Blut. 41: 41 1980;
    CrossrefPubMedGoogle Scholar
  • 35 Green A. J, Ratnoff O. D. Elevated antihaemophilic factor (AHF, factor VIII) procoagulant activity and AHF-like antigen in alcoholic cirrhosis of the liver. J. Lab. Clin. Med. 83: 189 1974;
    PubMedGoogle Scholar
  • 36 Green G, Poller L, Thomson J. M, Dymock J. W. Factor VII as a marker of hepatocellular synthetic function in liver disease. J. Clin. Path. 29: 971 1976;
    CrossrefPubMedGoogle Scholar
  • 37 Green G, Thomson J. M, Dymock I. W, Poller L. Abnormal fibrin polymerization in liver disease. Brit. J. Haematol. 34: 425 1976;
    PubMedGoogle Scholar
  • 38 Harenberg J, Hepp G, Schmidt-Gayk H. Fibrinopeptide A in human plasmaevaluation of a new radioimmunassay technique on microliter plates. Thromb. Res. 15: 513 1979;
    CrossrefPubMedGoogle Scholar
  • 39 Hedner U, Nilsson J. M. Antithrombin III in a clinical material. Thromb. Res. 03: 631 1973;
    CrossrefPubMedGoogle Scholar
  • 40 Heene D. L. Gerinnungsstörung bei portaler Hypertension. Z. Gastroent. 13: 147 1975;
    PubMedGoogle Scholar
  • 41 Hillenbrand P, Parbhoo S. P, Jedrychowski A, Sherlock S. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut. 15: 83 1974;
    CrossrefPubMedGoogle Scholar
  • 42 Hiller E, Hegemann F, Possinger K. Hypercoagulability in acute esophageal variceal bleeding. Thromb. Res. 22: 243 1981;
    CrossrefPubMedGoogle Scholar
  • 43 Klingemann H. G, Egbring R, Havemann K. Structure of fibrin and fibrin monomer in renal and hepatic failure. Klin. Wschr. 58: 533 1980;
    CrossrefPubMedGoogle Scholar
  • 44 Koj A. Acute-phase reactants their synthesis, turnover and biological significance. In: Allison A. L. Structure and Function of Plasma Proteins. Vol. 1. Plenum Press; London: 1974: 73.
    Google Scholar
  • 45 Kühn H. A, Liehr H. Systemische Hämodynamik und Blutgerinnung bei portaler Hypertension. Med. Klin. 72: 1713 1977;
    PubMedGoogle Scholar
  • 46 Kupfer H. G. Statistical correlation of liver function tests with coagulation factor deficiencies in Laenec’s cirrhosis. Thromb. Diath. Haemorrhag. 10: 317 1963;
    PubMedGoogle Scholar
  • 47 Lasch H. G. Umsatzstörungen der Hämostase bei chronischen Lebererkrankungen. In: Neumayr A. (Hrsg.): Aktuelle Probleme der klinischen Hepatologie. Witzstrock: Baden-Baden; 1975: 63.
    Google Scholar
  • 48 Lasch H. G, Müller-Berghaus G. Prokontra: Verbrauchskoagulopathie - Heparinbehandlung? Argumente für eine Heparinbehandlung. Internist. 21: 382 1980;
    PubMedGoogle Scholar
  • 49 Laursen B, Mortensen J. Z, Frist L, Hansen K. B. Disseminated intravascular coagulation in hepatic failure treated with antithrombin III. Thromb. Res. 22: 701 1981;
    CrossrefPubMedGoogle Scholar
  • 50 Laursen B, Frost L, Mortensen J. Z, Hansen K. B, Paulsen S. M. Acute fatty liver of pregnancy with complicating disseminated intravascular coagulation. Acta Obstet. Gynecol. Scand. 62: 403 1983;
    CrossrefPubMedGoogle Scholar
  • 51 Lenz K, Kleinberger G, Druml W, Laggner A. Die Schockleber. Leber - Magen - Darm. 12: 198 1982;
    PubMedGoogle Scholar
  • 52 Le Veen H. H, Christoudias G, Moon P, Luft R, Falk G, Grosberg S. Peritoneovenous shunting for ascites. Ann. Surg. 180: 500 1974;
    PubMedGoogle Scholar
  • 53 Liebmann H. A, McGehee W. G, Patch M. J, Feinstein D. I. Severe depression of AT III associated with disseminated intravascular coagulation in women with fatty liver of pregnancy. Ann. Intern. Med. 98: 330 1983;
    CrossrefPubMedGoogle Scholar
  • 54 Lipsky J. J. N-Methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinemia. Lancet. II: 192 1983;
    PubMedGoogle Scholar
  • 55 Macdougall B. R. D, Bailey R. J, Williams R. H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trialsLancet. I: 617 1977;
    PubMedGoogle Scholar
  • 56 Mammen E. F. Protein C und S. Hämo- staseologie. 04: 138 1984;
    PubMedGoogle Scholar
  • 57 Mannucci L, Dioguardi N, Del Nimo E, Mannucci P. M. Value of normotest and antithrombin III in the assessment of liver function. Scand. J. Gastroenterol. 08 (Suppl. 19): 103 1973;
    CrossrefPubMedGoogle Scholar
  • 58 Mannucci P. M. Estimation of prothrombin in liver disease. J. Clin. Pathol. 23: 291 1970;
    CrossrefPubMedGoogle Scholar
  • 59 Mannucci P. M, Franci F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet. II: 542 1976;
    PubMedGoogle Scholar
  • 60 Mannucci P. M, Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet. II: 463 1982;
    PubMedGoogle Scholar
  • 61 Martinez J, Palascak J. E, Kwasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J. Clin. Invest 61: 535 1978;
    CrossrefPubMedGoogle Scholar
  • 62 Matthias F. R. Umsatzstörungen im Gerinnungs- und Fibrinolysesystem durch Erkrankungen der Leber. Schwerpunktmed. 05: 21 1982;
    PubMedGoogle Scholar
  • 63 Matthias F. R. Blutgerinnungsstörungen. Hämorrhagische Diathesen und thromboembolische Erkrankungen. Springer, Berlin - Heidelberg: 1985: 113.
    Google Scholar
  • 64 Neidhardt B, Schricker T. hK. Hämostasestörungen bei Leberzirrhose. Teil 2: Therapie. Fortschr. Med. 100: 836 1982;
    PubMedGoogle Scholar
  • 65 Oehler G, Bleyl H, Bischoff B, Henk R. Vergleich von Prothrombin-Aktivität und -konzentration bei verschiedenen Funktionszuständen der Leber. Verh. Dtsch. Ges. Inn. Med. 80: 1452 1974;
    PubMedGoogle Scholar
  • 66 Oehler G, Matthias F. R. Affinitätschromatographische Fibrinmonomer-Bestimmung bei chronischen Lebererkrankungen. Verh. Dtsch. Ges. Inn. Med. 85: 481 1979;
    PubMedGoogle Scholar
  • 67 Oehler G, Bleyl H, Röka L. Immunologische Prothrombinbestimmung bei Patienten mit Leberkrankheiten. In: Fibrinolyse, Thrombose, Hämostase. Deutsch, E., K. Lechner (Hrsg.). Schattauer, Stuttgart -New York; 1980: 135.
    Google Scholar
  • 68 Oehler G, Lasch H. G. Gerinnungsstörungen im Schock. In: Handbuch der Inneren Riecker Medizin, G. (Hrsg.). Bd. IX/ 2: Schock.. Springer, Berlin - Heidelberg - New York: 1984: 203.
    Google Scholar
  • 69 Oehler G, Matthes K. Protein C in various liver diseases. In: Witt J. (Ed.): Protein C. Proceedings of the International Workshop on Biochemical and Medical Aspects of Protein C, Titisee, July 9-11, 1984. de Gruyter. Berlin - New York (im Druck).:
    Google Scholar
  • 70 Oka K, Tanaka K. Local fibrinolysis of esophagus and stomach as a cause of hemorrhage in liver cirrhosis. Thromb. Res. 14: 837 1979;
    CrossrefPubMedGoogle Scholar
  • 71 Orlando M, Casalbore P, Camagna A, Lauro R, Tardella L, Hassan H. J. Factor VII in liver cirrhosis. Haemostasis. 11: 73 1982;
    PubMedGoogle Scholar
  • 72 Ostermann H, Kirchhoff B, Pott G. Prothrombin determination in plasma and in liver biopsies in chronic liver diseases. Res. exp. med. 180: 271 1982;
    CrossrefPubMedGoogle Scholar
  • 73 Pabinger-Fasching J. Protein C - ein in der Leber gebildeter Gerinnungsinhibitor. Hämostaseologie. 04: 50 1984;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Pakter R. L, Russel T. R, Meilke C. H, West D. Coagulopathy associated with the use of moxalactam. Jama. 248: 1100 1982;
    CrossrefPubMedGoogle Scholar
  • 75 Palascak J. E, Martinez J. Dysfibrinogenemia associated with liver disease. J. Clin. Invest. 60: 89 1977;
    CrossrefPubMedGoogle Scholar
  • 76 Ragni M. V, Lewis J. H, Spero J. A, Hariba U. Bleeding and coagulation abnormalities in alcoholic cirrhotic liver disease. Alcoholism. 06: 267 1980;
    PubMedGoogle Scholar
  • 77 Rake M. O, Flute P. T, Panell G, Williams R. Intravascular coagulation in acute hepatic necrosis. Lancet. I: 533 1970;
    PubMedGoogle Scholar
  • 78 Ronneberger H, Hein B. Effect of antithrombin III on experimental intoxications with hepatotoxins in dogs. Toxicology Letters. 01: 179 1980;
    PubMedGoogle Scholar
  • 79 Rubin M. H, Werton M. J, Langley P. G, White Y, Williams R. Platelet function in chronic liver disease. Relation to disease severity. Dig. Dis. Sci. 24: 197 1979;
    CrossrefPubMedGoogle Scholar
  • 80 Ruiz F, Grainger S. L, Hall R. J. C, Ingram G. I. C, Pollard V, Swan A. V. Relation of simple clotting tests to clotting factor levels in liver disease. Clin. lab. Haemat. 04: 247 1982;
    PubMedGoogle Scholar
  • 81 Sbarbaro J. A, Bennett R. M. Aspirin hepatotoxicity and disseminated intravascular coagulation. Ann. intern. Med. 86: 183 1977;
    CrossrefPubMedGoogle Scholar
  • 82 Scharf R. E, Schneider W, Heisig S, Schramm W. Thrombozytopenie bei Leberzirrhose. Klin. Wschr. 61: 703 1983;
    CrossrefPubMedGoogle Scholar
  • 83 Scharf R. E, Heisig S, Winkelmann M, Schneider W. Erhöhte thrombozytäre Sialinsäurekonzentration bei Leberzirrhose. Verh. Dtsch. Ges. Inn. Med. 89: 990 1983;
    PubMedGoogle Scholar
  • 84 Schipper G. H, Henkins G. S. P, Kahle L. H, Tencate J. W. AT Ill-transfusion in disseminated intravascular coagulation. Lancet. I: 854 1978;
    PubMedGoogle Scholar
  • 85 Schneider W, Scharf R. E, Schramm W. Thrombozyten und Lebererkrankungen. Verh. Dtsch. Ges. Inn. Med. 88: 1336 1982;
    PubMedGoogle Scholar
  • 86 Schuster H. P, Prellwitz W, Schönborn H, Olbermann M. Blutgerinnungsstörungen als Mitursache massiver gastrointestinaler Blutungen bei Patienten mit Leberzirrhose. Med. Welt. 27: 1392 1976;
    PubMedGoogle Scholar
  • 87 Schwarz M. L, Swame W. R, Vogel S. B. Coagulopathy following peritoneovenous shunting. Surgery. 85: 671 1979;
    PubMedGoogle Scholar
  • 88 Simert G, Lundequist A, Tylén U. Correlation between percutaneous transhepatic portography and clinical findings in 56 patients with portal hypertension. Acta chir. Scand. 144: 27 1978;
    PubMedGoogle Scholar
  • 89 Singh R, Singh M. M, Hazra D. K, Agarwal N, Patney N. L, Goyal S. P, Bausal O. P, Mekrotas M. P, Sherma S. K. A study of disseminated intravascular coagulopathy in hepatic coma complicating acute viral hepatitis. Angiology. 34: 470 1983;
    CrossrefPubMedGoogle Scholar
  • 90 Soria J, Soria C, Samama M, Coupler J, Girard M. L, Bousser J, Pasquier-Bilski G. Dysfibrinogénémia acquises dans les atteintes hépatiques sévères. Coagulation. 03: 37 1970;
    PubMedGoogle Scholar
  • 91 Spero J. A, Lewis J. H, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thrombos. Haemostas. 43: 28 1980;
    PubMedGoogle Scholar
  • 92 Stein S. F, Harker L. A. Kinetic and functional studies of platelets, fibrinogen and plasminogen in patients with hepatic cirrhosis. J. Lab. Clin. Med. 99: 217 1982;
    PubMedGoogle Scholar
  • 93 Straub P. W. Diffuse intravascular coagulation in liver disease? Semin. Thromb. Haemostas. 04: 29 1977;
    PubMedGoogle Scholar
  • 94 Straub P. W. Pro-kontra: Verbrauchskoagulopathie - Heparinbehandlung? Argumente gegen eine Heparinbehandlung. Internist. 21: 385 1980;
    PubMedGoogle Scholar
  • 95 Tytgat G. N, Collen D, Verstraete M. Metabolism of fibrinogen in cirrhosis of the liver. J. Clin. Invest. 50: 1690 1971;
    CrossrefPubMedGoogle Scholar
  • 96 Verstraete M, Vermylen J, Collen D. Intravascular coagulation in liver disease. Ann. Rv. Med. 25: 447 1974;
    PubMedGoogle Scholar
  • 97 Vogel G. E, Clarmann M. v. Therapie bei Knollenblätterpilzvergiftung. Umweltmedizin. 03: 41 1981;
    PubMedGoogle Scholar
  • 98 Vogel G. E, Clarmann M. v, Komm C. h, Oberdörfer A. Die Therapie mit Antithrombin III (AT III) beim akuten Leberversagen (ALV). In: Blümel G, Haas S. (Hrsg.): Mikrozirkulation und Prostaglandinstoffwechsel. Verhandlungs- bericht der 25. Tagung der Deutschen Arbeitsgemeinschaft für Blutgerinnungsforschung, München. 1981: 471.
    Google Scholar
  • 99 Vogel G. E, Komm C. h, Lorenz R, Bottermann P. Das akute Leberversagen - neue therapeutische Aspekte. Intensivbehandlung. 09: 60 1984;
    PubMedGoogle Scholar
  • 100 Vogel G. E. Substitution von Antithrombin III. Eine neue Therapiemöglichkeit bei schweren Lebererkrankungen. Hämostaseologie. 04: 54 1984;
    PubMedGoogle Scholar
  • 101 Walker J, Wilner R. A, Johnston M. A, Rand C. A, Neame P. B, Hirsh J. Factors XI and XII are low in subjects with liver disease. Dig. Dis. Sci. 28: 967 1983;
    CrossrefPubMedGoogle Scholar
  • 102 Weitekamp M, Aber R. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 249: 69 1983;
    CrossrefPubMedGoogle Scholar
  • 103 Zimmermann R, Czygan P, Harenberg J, Kommereil B. Zur Bedeutung von Antithrombin III bei der hepatischen Hämostasestörung. Inn. Med. 09: 270 1982;
    PubMedGoogle Scholar
  • 104 Zwierzina W. D, Kunz F, Judmaier G, Mikuz G, Gattringer K. Akute Schwangerschaftsfettleber mit Verbrauchskoagu- lopathie. Dtsch. med. Wschr. 108: 703 1983;
    Article in Thieme ConnectPubMedGoogle Scholar